Evaluation of orelabrutinib monotherapy in patients with relapsed or refractory Waldenström's macroglobulinemia in a single-arm, multicenter, open-label, phase 2 study

BACKGROUND: Orelabrutinib is a novel, small molecule, selective irreversible Bruton tyrosine kinase inhibitor. The purpose of this study was to evaluate the efficacy and safety of orelabrutinib in patients with relapsed or refractory Waldenström's macroglobulinemia (R/R WM). METHODS: This is a...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Xin-xin, Jin, Jie, Fu, Cheng-cheng, Yi, Shu-hua, Zhao, Wei-li, Sun, Zi-min, Yang, Wei, Li, Deng-ju, Cui, Guo-hui, Hu, Jian-da, Liu, Ting, Song, Yong-ping, Xu, Bing, Zhu, Zun-min, Xu, Wei, Zhang, Ming-zhi, Tian, Ya-min, Zhang, Bin, Zhao, Ren-bin, Zhou, Dao-bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9596308/
https://www.ncbi.nlm.nih.gov/pubmed/36313145
http://dx.doi.org/10.1016/j.eclinm.2022.101682

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9596308/
https://www.ncbi.nlm.nih.gov/pubmed/36313145
http://dx.doi.org/10.1016/j.eclinm.2022.101682

Ejemplares similares